Skin Disease Treatment Technologies and Global Markets
The global dermatology markets reached $15.8 billion in 2012. The market is expected to reach $16.1 billion in 2013 and $18.5 billion in 2018 for a CAGR of 2.8%.
- An overview of the global market for treatments of skin diseases, perhaps the most common of human afflications
- Analyses of global market trends, with data from 2011 and 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
- Focused coverage of four major categories of skin disease of exceptional medical and commercial significance: dermatitis (allergic and contact), cancers (including melanoma), immune disorders (including psoriasis), and infections (bacterial, fungal and viral)
- Topics such as skin structure and function, diseases of the skin, current treatment options, and unmet clinical needs
- Discussion of the evolution of the market, including the rising prevalence of some skin diseases, and new diagnostic and treatment options
- Examination of the global market by product categories, such as anti-allergic products, antibacterials, antifungals, antivirals, immunotherapies, and anticancers
- Comprehensive company profiles of major players.
SCOPE OF REPORT
This report discusses the implications of the above-mentioned trends in the context of the current size and growth of the dermatology market, discussed both in global terms and in reference to the most important national markets. Long-standing and emerging companies are discussed, with profiles of their leaders and an update on M&A activity. Five-year global sales forecasts are provided for main drug categories, and breakdowns are provided for several national markets.
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of several previous BCC reports on diseases affecting different organ systems in addition to the skin.